Drug intelligence / Profile preview

sodium chloride + dexamethasone

Development stage: Approved
Lead developer: Quince Therapeutics
Modality: Small Molecules
Administration: Injection, Subcutaneous

Overview

A combination of sodium chloride (saline) and dexamethasone (a synthetic glucocorticoid). This combination is primarily used in palliative care settings where dexamethasone 3.3mg/ml solution for injection is diluted with sodium chloride injection for administration via Continuous Subcutaneous Infusion. Sodium chloride serves as the diluent or vehicle, enabling proper administration and absorption. Dexamethasone itself is a potent anti-inflammatory and immunosuppressive medication that regulates the body's metabolism and immune response.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on sodium chloride + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium chloride + dexamethasone.

Explore the full profile